Dr. Brenner is an assistant professor in the Department of Otolaryngology-Head and Neck Surgery. He is also a member of the U-M Rogel Cancer Center. His lab, the Michigan Otolaryngology and Translational Oncology lab (MiOTO), aims to identify new diagnostic tests and precision medicine therapies for cancer patients.
In addition to receiving his undergraduate degree in biomedical engineering from the University of Michigan, Brenner also received a master's in engineering in bioelectrical engineering and a doctorate in cellular and molecular biology for his seminal contributions to molecular mechanisms of prostate cancer progression and therapeutic inhibition of the disease.
Areas of Interest
Dr. Brenner's research is focused on functional genomic, proteomic and bioinformatics approaches to study cancer to discover novel therapeutic approaches that benefit patients (precision medicine) and to help understand the mechanisms that drive cancer progression. Brenner’s lab has identified novel approaches to overcome PI3K and EGFR inhibitor resistance pathways in head and neck squamous cell carcinoma as well as discovered novel driving lesions in clinically aggressive mucoepidermoid carcinomas. Current studies build on this previous work and are now focused on understanding how tumor cells and the surrounding microenvironment adapt to precision-guided therapies, including immunotherapy, with the goal of identifying new clinical trials that may benefit each head and neck cancer patient. Additional research is focused on understanding how to leverage precision-guided therapies to improve the immune response to cancer, and if immune checkpoint inhibitors can be used to prevent cancer initiation. Brenner and his team are also interested in advancing liquid biomarker (blood or saliva) based tests that can be used for early detection of disease and to give real time information on each patients response to treatment.
Honors & Awards
Dr. Brenner has received a number of awards including the Lindau-Nobel Graduate Student Award, the American Association for Cancer Research Scientist in Training in Award, and the Prostate Cancer Foundation Young Investigator Award.
Researchers find infiltrating lymphocytes tie to survival in patients with recurrent larynx cancer; findings suggest super-boosting the immune system before additional treatment.
In a new paper, researchers and ethicists urge policymakers to view immortal cells differently from other biospecimens as new rules go into effect.